Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
© 2024. The Author(s)..
Although vaccines are available for SARS-CoV-2, antiviral drugs such as nirmatrelvir are still needed, particularly for individuals in whom vaccines are less effective, such as the immunocompromised, to prevent severe COVID-19. Here we report an α-ketoamide-based peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), designated RAY1216. Enzyme inhibition kinetic analysis shows that RAY1216 has an inhibition constant of 8.4 nM and suggests that it dissociates about 12 times slower from Mpro compared with nirmatrelvir. The crystal structure of the SARS-CoV-2 Mpro:RAY1216 complex shows that RAY1216 covalently binds to the catalytic Cys145 through the α-ketoamide group. In vitro and using human ACE2 transgenic mouse models, RAY1216 shows antiviral activities against SARS-CoV-2 variants comparable to those of nirmatrelvir. It also shows improved pharmacokinetics in mice and rats, suggesting that RAY1216 could be used without ritonavir, which is co-administered with nirmatrelvir. RAY1216 has been approved as a single-component drug named 'leritrelvir' for COVID-19 treatment in China.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Nature microbiology - 9(2024), 4 vom: 29. Apr., Seite 1075-1088 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Xiaoxin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41564-024-01618-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370431316 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370431316 | ||
| 003 | DE-627 | ||
| 005 | 20240426234053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41564-024-01618-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM370431316 | ||
| 035 | |a (NLM)38553607 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Xiaoxin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Although vaccines are available for SARS-CoV-2, antiviral drugs such as nirmatrelvir are still needed, particularly for individuals in whom vaccines are less effective, such as the immunocompromised, to prevent severe COVID-19. Here we report an α-ketoamide-based peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), designated RAY1216. Enzyme inhibition kinetic analysis shows that RAY1216 has an inhibition constant of 8.4 nM and suggests that it dissociates about 12 times slower from Mpro compared with nirmatrelvir. The crystal structure of the SARS-CoV-2 Mpro:RAY1216 complex shows that RAY1216 covalently binds to the catalytic Cys145 through the α-ketoamide group. In vitro and using human ACE2 transgenic mouse models, RAY1216 shows antiviral activities against SARS-CoV-2 variants comparable to those of nirmatrelvir. It also shows improved pharmacokinetics in mice and rats, suggesting that RAY1216 could be used without ritonavir, which is co-administered with nirmatrelvir. RAY1216 has been approved as a single-component drug named 'leritrelvir' for COVID-19 treatment in China | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Lactams |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Huang, Xiaodong |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Qinhai |e verfasserin |4 aut | |
| 700 | 1 | |a Kuzmič, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Biao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Sai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jizheng |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jinxin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wenjie |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chunguang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shiguan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jianzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Haijun |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Chaofeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Hongrui |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Yanan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yaoting |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Chuanying |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jinsong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tianyu |e verfasserin |4 aut | |
| 700 | 1 | |a Spencer, James |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Zhenzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Wenbin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xinwen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shu-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Nanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zifeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature microbiology |d 2016 |g 9(2024), 4 vom: 29. Apr., Seite 1075-1088 |w (DE-627)NLM257483241 |x 2058-5276 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:4 |g day:29 |g month:04 |g pages:1075-1088 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41564-024-01618-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 4 |b 29 |c 04 |h 1075-1088 | ||